A Randomised, Double-blind, Double-dummy, Parallel Group, International (Asian), Multicenter, Phase 3 Study to Assess Safety and Efficacy of AZD6140 on Top of Low Dose Acetyl Salicylic Acid (ASA) Versus Clopidogrel on Top of Low Dose ASA in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) for Whom PCI is Planned

Trial Profile

A Randomised, Double-blind, Double-dummy, Parallel Group, International (Asian), Multicenter, Phase 3 Study to Assess Safety and Efficacy of AZD6140 on Top of Low Dose Acetyl Salicylic Acid (ASA) Versus Clopidogrel on Top of Low Dose ASA in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) for Whom PCI is Planned

Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2016

At a glance

  • Drugs Ticagrelor (Primary) ; Clopidogrel
  • Indications Acute coronary syndromes; Cardiovascular disorders; Embolism and thrombosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms PHILO
  • Sponsors AstraZeneca
  • Most Recent Events

    • 16 Sep 2015 Results published in the Circulation Journal.
    • 18 Jul 2012 PHILO added as the trial acronym as reported in an AstraZeneca media release.
    • 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top